Resultados: 16

    AGA clinical practice guideline on the role of biomarkers for the management of Crohn’s Disease

    Gastroenterology; 6 (165), 2023
    Biomarkers are used frequently for evaluation and monitoring of patients with Crohn’s disease (CD). This American Gastroenterological Association (AGA) guideline is intended to support practitioners in decisions about the use of biomarkers for the management of CD. A multidisciplinary panel of content ...

    AGA clinical practice update on risk stratification for colorectal cancer screening and post-polypectomy surveillance: expert review

    Gastroenterology; 165 (5), 2023
    Since the early 2000s, there has been a rapid decline in colorectal cancer (CRC) mortality, due in large part to screening and removal of precancerous polyps. Despite these improvements, CRC remains the second leading cause of cancer deaths in the United States, with approximately 53,000 deaths projected...

    AGA clinical practice update on the epidemiology, evaluation, and management of exocrine pancreatic insufficiency: expert review

    Gastroenterology; 165 (5), 2023
    Exocrine pancreatic insufficiency (EPI) is a disorder caused by the failure of the pancreas to deliver a minimum/ threshold level of specific pancreatic digestive enzymes to the intestine, leading to the maldigestion of nutrients and macronutrients, resulting in their variable deficiencies. EPI is freque...

    AGA clinical practice guideline on the role of biomarkers for the management of ulcerative colitis

    Gastroenterology; 164 (3), 2023
    Biomarkers are used frequently for noninvasive monitoring and treatment decision making in the management of patients with ulcerative colitis (UC). This American Gastroenterological Association (AGA) guideline is intended to support practitioners in decisions about the use of biomarkers for the managemen...

    AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity

    Gastroenterology; 163 (5), 2022
    Pharmacological management of obesity improves outcomes and decreases the risk of obesity-related complications. This American Gastroenterological Association guideline is intended to support practitioners in decisions about pharmacological interventions for overweight and obesity. A multidisciplinary pa...

    AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea

    Gastroenterology; 163 (1), 2022
    Background & aims: Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder associated with significant disease burden. This American Gastroenterological Association Guideline is intended to support practitioners in decisions about the use of medications for the pharmacological man...

    AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation

    Gastroenterology; 163 (1), 2022
    Irritable bowel syndrome (IBS) is a common disorder of gut–brain interaction associated with significant disease burden. This American Gastroenterological Association guideline is intended to support practitioners in decisions about the use of medications for the pharmacological management of IBS-C and...

    AGA clinical practice update on the diagnosis and management of Atrophic Gastritis: expert review

    Gastroenterology; 161 (4), 2021
    The purpose of this Clinical Practice Update Expert Review is to provide clinicians with guidance on the diagnosis and management of atrophic gastritis, a common preneoplastic condition of the stomach, with a primary focus on atrophic gastritis due to chronic Helicobacter pylori infection-the most common...

    AGA rapid review and guideline for SARS-CoV2 testing and endoscopy post-vaccination: 2021 update

    Gastroenterology; 161 (3), 2021
    This guideline provides updated recommendations on the role of preprocedure testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) in individuals undergoing endoscopy in the post-vaccination period and replaces the prior guideline from the American Gastroenterological Association (AGA) (...

    Canadian Association of Gastroenterology clinical practice guideline for immunizations in patients with inflammatory Bowel Disease (IBD)-Part 2: inactivated vaccines

    Gastroenterology; 161 (2), 2021
    The effectiveness and safety of vaccinations can be altered by immunosuppressive therapies, and perhaps by inflammatory bowel disease (IBD) itself. These recommendations developed by the Canadian Association of Gastroenterology and endorsed by the American Gastroenterological Association, aim to provide ...